Impact on HIV-1 RNA Levels and Antibody Responses Following SARS-CoV-2 Vaccination in HIV-Infected Individuals
This study aims to assess the immunological response and impact on virological control of the mRNA vaccines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among people living with HIV (PLWH). In this single-center observational study, all PLWH were offered vaccination with mRNA1273...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-02-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.820126/full |
| _version_ | 1818331381841788928 |
|---|---|
| author | Vera Portillo Chiara Fedeli Pilar Ustero Alonso Ianis Petignat Ellen Cristina Mereles Costa Adi Sulstarova Cyril Jaksic Sabine Yerly Alexandra Calmy Alexandra Calmy |
| author_facet | Vera Portillo Chiara Fedeli Pilar Ustero Alonso Ianis Petignat Ellen Cristina Mereles Costa Adi Sulstarova Cyril Jaksic Sabine Yerly Alexandra Calmy Alexandra Calmy |
| author_sort | Vera Portillo |
| collection | DOAJ |
| description | This study aims to assess the immunological response and impact on virological control of the mRNA vaccines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among people living with HIV (PLWH). In this single-center observational study, all PLWH were offered vaccination with mRNA1273 or BNT162b2. Both anti-N and anti-S1-receptor binding domain (RBD) antibodies were measured together with HIV-1 RNA levels after the first dose (M0) and then at 1 (M1), 2 (M2) and 6 (M6) months later. A total of 131 individuals (median age: 54 years [IQR: 47.0-60.5]; male: 70.2%; median baseline CD4 T-cell: 602/µl [IQR 445.0-825.5]; median nadir CD4 T-cells 223/µl [IQR 111.0-330.0]) were included. All participants were positive for anti-RBD antibodies at 30 days, 60 days and 6 months after the first dose, with no statistical difference between those with HIV-1 RNA below or >20 copies/ml. HIV-1 RNA data were collected for 128 patients at baseline and 30 days after the first dose; for 124 individuals, 30 days after the second dose; and for 83 patients, 6 months after the first dose. Nineteen (14.8%) of 128 had detectable HIV-1 RNA (>20 copies/ml) at M0, 13/128 (10.2%) at M1 (among which 5 were newly detectable), 15/124 (12.1%) at M2 (among which 5 were newly detectable), and 8/83 (9.6%) at M6. No serious adverse effects were reported. All participants elicited antibodies after two doses of mRNA vaccines, with only a minor impact on HIV-1 RNA levels over a 6-month period. |
| first_indexed | 2024-12-13T13:18:57Z |
| format | Article |
| id | doaj.art-0755b8859b1748c281d4d9e18ce1b260 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-13T13:18:57Z |
| publishDate | 2022-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-0755b8859b1748c281d4d9e18ce1b2602022-12-21T23:44:27ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-02-011210.3389/fimmu.2021.820126820126Impact on HIV-1 RNA Levels and Antibody Responses Following SARS-CoV-2 Vaccination in HIV-Infected IndividualsVera Portillo0Chiara Fedeli1Pilar Ustero Alonso2Ianis Petignat3Ellen Cristina Mereles Costa4Adi Sulstarova5Cyril Jaksic6Sabine Yerly7Alexandra Calmy8Alexandra Calmy9Division of Infectious Diseases, Geneva University Hospitals, Geneva, SwitzerlandDivision of Infectious Diseases, Geneva University Hospitals, Geneva, SwitzerlandDivision of Infectious Diseases, Geneva University Hospitals, Geneva, SwitzerlandDivision of Infectious Diseases, Geneva University Hospitals, Geneva, SwitzerlandDivision of Infectious Diseases, Geneva University Hospitals, Geneva, SwitzerlandDivision of Infectious Diseases, Geneva University Hospitals, Geneva, SwitzerlandClinical Research Centre (CRC) & Division of Clinical Epidemiology, Department of Health and Community Medicine, University of Geneva and Geneva University Hospitals, Geneva, SwitzerlandDivision of Laboratory Medicine, Geneva University Hospitals, and Centre for Emerging Viral Diseases and Laboratory of Virology, Geneva University Hospitals, Geneva, SwitzerlandDivision of Infectious Diseases, Geneva University Hospitals, Geneva, SwitzerlandDepartment of Medicine, Faculty of Medicine, University of Geneva, Geneva, SwitzerlandThis study aims to assess the immunological response and impact on virological control of the mRNA vaccines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among people living with HIV (PLWH). In this single-center observational study, all PLWH were offered vaccination with mRNA1273 or BNT162b2. Both anti-N and anti-S1-receptor binding domain (RBD) antibodies were measured together with HIV-1 RNA levels after the first dose (M0) and then at 1 (M1), 2 (M2) and 6 (M6) months later. A total of 131 individuals (median age: 54 years [IQR: 47.0-60.5]; male: 70.2%; median baseline CD4 T-cell: 602/µl [IQR 445.0-825.5]; median nadir CD4 T-cells 223/µl [IQR 111.0-330.0]) were included. All participants were positive for anti-RBD antibodies at 30 days, 60 days and 6 months after the first dose, with no statistical difference between those with HIV-1 RNA below or >20 copies/ml. HIV-1 RNA data were collected for 128 patients at baseline and 30 days after the first dose; for 124 individuals, 30 days after the second dose; and for 83 patients, 6 months after the first dose. Nineteen (14.8%) of 128 had detectable HIV-1 RNA (>20 copies/ml) at M0, 13/128 (10.2%) at M1 (among which 5 were newly detectable), 15/124 (12.1%) at M2 (among which 5 were newly detectable), and 8/83 (9.6%) at M6. No serious adverse effects were reported. All participants elicited antibodies after two doses of mRNA vaccines, with only a minor impact on HIV-1 RNA levels over a 6-month period.https://www.frontiersin.org/articles/10.3389/fimmu.2021.820126/fullSARS-CoV-2HIVvaccinationPLWHserology |
| spellingShingle | Vera Portillo Chiara Fedeli Pilar Ustero Alonso Ianis Petignat Ellen Cristina Mereles Costa Adi Sulstarova Cyril Jaksic Sabine Yerly Alexandra Calmy Alexandra Calmy Impact on HIV-1 RNA Levels and Antibody Responses Following SARS-CoV-2 Vaccination in HIV-Infected Individuals Frontiers in Immunology SARS-CoV-2 HIV vaccination PLWH serology |
| title | Impact on HIV-1 RNA Levels and Antibody Responses Following SARS-CoV-2 Vaccination in HIV-Infected Individuals |
| title_full | Impact on HIV-1 RNA Levels and Antibody Responses Following SARS-CoV-2 Vaccination in HIV-Infected Individuals |
| title_fullStr | Impact on HIV-1 RNA Levels and Antibody Responses Following SARS-CoV-2 Vaccination in HIV-Infected Individuals |
| title_full_unstemmed | Impact on HIV-1 RNA Levels and Antibody Responses Following SARS-CoV-2 Vaccination in HIV-Infected Individuals |
| title_short | Impact on HIV-1 RNA Levels and Antibody Responses Following SARS-CoV-2 Vaccination in HIV-Infected Individuals |
| title_sort | impact on hiv 1 rna levels and antibody responses following sars cov 2 vaccination in hiv infected individuals |
| topic | SARS-CoV-2 HIV vaccination PLWH serology |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2021.820126/full |
| work_keys_str_mv | AT veraportillo impactonhiv1rnalevelsandantibodyresponsesfollowingsarscov2vaccinationinhivinfectedindividuals AT chiarafedeli impactonhiv1rnalevelsandantibodyresponsesfollowingsarscov2vaccinationinhivinfectedindividuals AT pilarusteroalonso impactonhiv1rnalevelsandantibodyresponsesfollowingsarscov2vaccinationinhivinfectedindividuals AT ianispetignat impactonhiv1rnalevelsandantibodyresponsesfollowingsarscov2vaccinationinhivinfectedindividuals AT ellencristinamerelescosta impactonhiv1rnalevelsandantibodyresponsesfollowingsarscov2vaccinationinhivinfectedindividuals AT adisulstarova impactonhiv1rnalevelsandantibodyresponsesfollowingsarscov2vaccinationinhivinfectedindividuals AT cyriljaksic impactonhiv1rnalevelsandantibodyresponsesfollowingsarscov2vaccinationinhivinfectedindividuals AT sabineyerly impactonhiv1rnalevelsandantibodyresponsesfollowingsarscov2vaccinationinhivinfectedindividuals AT alexandracalmy impactonhiv1rnalevelsandantibodyresponsesfollowingsarscov2vaccinationinhivinfectedindividuals AT alexandracalmy impactonhiv1rnalevelsandantibodyresponsesfollowingsarscov2vaccinationinhivinfectedindividuals |